Literature DB >> 34911674

Nivolumab-induced multiple morphea associated with eosinophilic fasciitis.

Marouschka Lacombe1, Christophe Bedane1, Stéphanie Delaumenie1, Philippe Bernard1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34911674      PMCID： PMC8853320          DOI： 10.1684/ejd.2021.4181

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN： 1167-1122            Impact factor:   3.328


× No keyword cloud information.
  8 in total

1.  Eosinophilic fasciitis and lichen sclerosus in a patient treated with nivolumab.

Authors:  Juan-José Andrés-Lencina; Sara Burillo-Martínez; Raquel Aragón-Miguel; Alba Calleja-Algarra; José-Luis Rodríguez-Peralto; Pablo-Luis Ortiz-Romero; Vanessa Gargallo-Moneva
Journal:  Australas J Dermatol       Date:  2018-05-24       Impact factor: 2.875

2.  Nivolumab-induced plaque morphea in a malign melanoma patient.

Authors:  Ayda Acar; Gokturk Oraloglu; Banu Yaman; Isil Karaarslan
Journal:  J Cosmet Dermatol       Date:  2020-12-28       Impact factor: 2.696

3.  Checkpoint inhibitor-induced eosinophilic fasciitis following high eosinophilia associated with complete response.

Authors:  Frédéric Toussaint; Matthias Hammon; Michael Erdmann; Alvaro Moreira; Michael C Kirchberger; Gerold Schuler; Georg Schett; Lucie Heinzerling
Journal:  Rheumatology (Oxford)       Date:  2019-10-01       Impact factor: 7.580

4.  Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapy.

Authors:  Kei Ohnuma; Ryo Hatano; Nam H Dang; Chikao Morimoto
Journal:  Mod Rheumatol       Date:  2018-12-20       Impact factor: 3.023

Review 5.  Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature.

Authors:  Karmela Kim Chan; Cynthia Magro; Alexander Shoushtari; Charles Rudin; Veronica Rotemberg; Anthony Rossi; Cecilia Lezcano; John Carrino; David Fernandez; Michael A Postow; Arlyn Apollo; Mario E Lacouture; Anne R Bass
Journal:  Oncologist       Date:  2019-10-15

6.  Risk of scleroderma according to the type of immune checkpoint inhibitors.

Authors:  Benjamin Terrier; Sébastien Humbert; Laure-Hélène Preta; Laure Delage; Jérôme Razanamahery; Sara Laurent-Roussel; Raphaële Mestiri; Lauren Beaudeau; Paul Legendre; François Goupil; Jérôme Hadjadj; Marie-Claude Stolzenberg; Jean-Marc Treluyer; Virginie Westeel; Marie-Blanche Valnet-Rabier; Marie Wislez; Luc Mouthon; Laurent Chouchana
Journal:  Autoimmun Rev       Date:  2020-06-12       Impact factor: 9.754

7.  Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors.

Authors:  Merav Lidar; Eitan Giat; Daniela Garelick; Yuval Horowitz; Howard Amital; Yael Steinberg-Silman; Jacob Schachter; Ronnie Shapira-Frommer; Gal Markel
Journal:  Autoimmun Rev       Date:  2018-01-16       Impact factor: 9.754

8.  Immunotherapy of melanoma.

Authors:  Iwona Lugowska; Pawel Teterycz; Piotr Rutkowski
Journal:  Contemp Oncol (Pozn)       Date:  2018-03-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.